7483-27-4

Upstream product

• 120-43-4 4-ethoxycarbonylpiperazine 
• 627-18-9 1-bromo-3-propanol 

Downstream Products

• 5317-32-8 3-(1-piperazinyl)-1-propanol 
• 1271943-25-9 3-{4-[3-(4-ethoxylphenoxy)propyl]piperazin-1-yl}-6-chloropyridazine 
• 1271943-27-1 3-{4-[3-(4-methylphenoxy)propyl]piperazin-1-yl}-6-chloropyridazine 
• 1271943-29-3 3-{4-[3-(4-ethylphenoxy)propyl]piperazin-1-yl}-6-chloropyridazine 
• 1271943-31-7 3-{4-[3-(4-isopropylphenoxy)propyl]piperazin-1-yl}-6-chloropyridazine 
• 1271943-33-9 4-{3-[4-(6-chloropyridazin-3-yl)piperazin-1-yl]propoxy}benzoic acid methyl ester 
• 124437-35-0 4-{3-[4-(6-chloropyridazin-3-yl)piperazin-1-yl]propoxy}benzoic acid ethyl ester 

Relevant academic research and scientific papers

PYRIDAZINE DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR TREATING MICRORNA VIRAL INFECTION

Disclosed are pyridazine derivatives represented by formula I or pharmaceutically acceptable salts or hydrates thereof, pharmaceutical compositions comprising the compounds, and the use of the compounds in preparing the medicaments for treating and/or preventing diseases or disorders associated with viral infections. The compounds represented by formula I have antiviral activity, especially anti-microRNA viral activity. Symbols in the compounds represented are described in the specification.

Pharmacophore-based design, synthesis, and biological evaluation of novel chloro-pyridazine piperazines as human rhinovirus (HRV-3) inhibitors

A series of chloro-pyridazine piperazines were developed based on the structure of human rhinovirus (HRV) capsid-binding inhibitors with proven activity using a pharmacophore model. A preliminary evaluation demonstrated potent activity against HRV-3 with low cytotoxicity. A docking analysis indicated that 8a could fit into, and form tight interactions (e.g., H-bonds, σ-π effect) with the active site in VP1.